Navigation Links
Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
Date:12/10/2007

Strengthens DBI's Portfolio of Technologies for Enabling Faster, Easier Quantification of Protein Biomarkers in Translational Medicine and Adaptive

Clinical Trials

WALTHAM, Mass., Dec. 10 /PRNewswire/ -- Decision Biomarkers Inc (DBI), a leading developer of protein biomarker analysis systems for pharmaceutical research and development, today announced the company's PATH(R) technology has been awarded United States Patent 7,297,497 by the U.S. Patent and Trademark Office. The patent applies to a novel, ultra-thin nitrocellulose surface chemistry that enables the detection of low-abundance proteins. This technology is integrated into DBI's AVANTRA(TM)Q400 Biomarker Workstation, a new, easy-to-use, immunoassay system that enables non-specialized technicians to perform complex protein biomarker analyses in the lab or directly at a clinical trial site.

Protein microarray glass slides utilizing the PATH(R) technology are also available from leading life science consumable suppliers to enable researchers to perform ultra sensitive assays including sandwich immunoassays, capture immunoassays, protein profiling, and protein characterization.

"Nitrocellulose has proven to be the protein-assay substrate of choice for decades. With this technology, researchers can use a wide variety of fluorescence probes to make protein assays easier, faster and more sensitive than ever before," said Roger Dowd, CEO and President of DBI. "By delivering a high signal-to-noise ratio and low background fluorescence, we believe the PATH(R) surface chemistry to be far superior to other commercially available protein-array surfaces."

The AVANTRA(TM)Q400 Biomarker Workstation, DBI's flagship product, is commercially available with various protein biomarker content including "off-the-shelf" multiplex biomarker panels for oncology, immunology, and cardiology, along with custom content defined by the Company's collaborators.

About Decision Biomarkers Inc

Decision Biomarkers is a privately-held life science tools company that has developed the next-generation technology for protein biomarker analysis. DBI is driving the widespread adoption of protein biomarker analysis with the first automated, multiplex immunoassay system that can be used in real-time by virtually anyone, anywhere in drug development, clinical trials and diagnostics. http://www.decisionbiomarkers.com

Copyright (C) 2007 Decision Biomarkers Inc. All rights reserved.


'/>"/>
SOURCE Decision Biomarkers Inc
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Consumer Advocates Praise Interstate Stem Cell Open Meeting Decision
2. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
3. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
4. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
5. New Data Reveal Ethnicity May Play Role in Weight Loss Decisions
6. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
7. NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007
8. Scientists Using Social Media to Inform Lab Purchasing Decisions
9. Ingenuity Systems Joins Biomarkers Consortium
10. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
11. Mirus Bio Awarded Grants & Contracts of Over $5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... its flagship CytoSorb® blood filter to treat deadly ... the world, announced that CEO Dr. Phillip ... Source Capital Group,s 2016 Disruptive Growth & Healthcare ... company.  Conference Presentation Details: ...
(Date:2/4/2016)... Md. , Feb. 4, 2016  Spherix Incorporated ... to the fostering and monetization of intellectual property, today ... and Uniden in the Northern District of ... moving forward.  Inter Partes Re-examination ... U.S. Patent Office.  The IPR was initiated on only ...
(Date:2/4/2016)... Brooklyn, NY (PRWEB) , ... February 04, 2016 , ... ... cuvettes for over 10 years. What sets them apart from other cuvette ... that is posted on their website. On top of this steady flow of ...
(Date:2/3/2016)... 2016 Ascendis Pharma A/S (Nasdaq: ASND ... innovative TransCon technology to address significant unmet medical needs, ... conference.Event:2016 Leerink Partners Global Healthcare Conference Location: , ... 10, 2016 Time:  , 11:55am EST ... An audio webcast of this event will be ...
Breaking Biology Technology:
(Date:1/20/2016)... , Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced sampling of S1423, its ... wearables and small screen applications including smartwatches, fitness ... Supporting round and rectangular shapes, as well as ... performance with moisture on screen, while wearing gloves, ...
(Date:1/13/2016)... 13, 2016 ... of the  "India Biometrics Authentication & ... (2015-2020)"  report to their offering.  ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ...
(Date:1/8/2016)... -- NXTD ), a company focused on ... privately held leading direct seller of vacation and entertainment ... company announced that on December 31, 2015, that WorldVentures ... to develop a proprietary new wireless smart card for ... unique smart wallet that serves to securely store all ...
Breaking Biology News(10 mins):